NEUROPROTECTION IN GLAUCOMA

Abstract

Glaucoma is one of the leading cause of bilindness all oer the world. It en be defined as a disease in which one of the pathophysiological consequences of raised intraocular pressure (lOP) is damage to the optic nerve and, subsequently, loss of the restinal ganglion cells. The fact that patients with glaucoma constinue to develop visual field defects long after the therapeutic normalizatiOn of their lOP suggests that elevated lOP alone cannot explain the propagation of glaucomatous optic neuropathy. .

However, many of these drugs have been used for the treatment of other conditions, and in order to achieve efficacy in glaucoma, should be used systmeically. This holds the risk of producing adverse reactions affecting otlier systems. Other drugs are still under clinical studies and are not available commercially.